Taisho Pharmaceutical Holdings Co., Ltd.
TAISF · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Market Cap | $452,879,993 | $442,883,440 | $592,996,613 | $510,488,200 |
| - Cash | $255,966,000 | $265,049,000 | $250,178,000 | $223,814,000 |
| + Debt | $2,590,000 | $3,503,000 | $2,591,000 | $3,106,000 |
| Enterprise Value | $199,503,993 | $181,337,440 | $345,409,613 | $289,780,200 |
| Revenue | $301,381,000 | $268,203,000 | $282,037,000 | $288,720,000 |
| % Growth | 12.4% | -4.9% | -2.3% | – |
| Gross Profit | $177,850,000 | $163,832,000 | $175,987,000 | $180,383,000 |
| % Margin | 59% | 61.1% | 62.4% | 62.5% |
| EBITDA | $54,315,000 | $44,642,000 | $45,173,000 | $41,824,000 |
| % Margin | 18% | 16.6% | 16% | 14.5% |
| Net Income | $18,997,000 | $13,122,000 | $13,316,000 | $20,172,000 |
| % Margin | 6.3% | 4.9% | 4.7% | 7% |
| EPS Diluted | 231.42 | 160.93 | 166.63 | 252.44 |
| % Growth | 43.8% | -3.4% | -34% | – |
| Operating Cash Flow | $40,972,000 | $28,506,000 | $42,026,000 | $41,992,000 |
| Capital Expenditures | -$50,379,000 | -$14,389,000 | -$14,372,000 | -$9,121,000 |
| Free Cash Flow | -$9,407,000 | $14,117,000 | $27,654,000 | $32,871,000 |